---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-095247"
form_type: "8-K"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2023-12-13T23:59:59+00:00"
generated_at: "2026-06-07T13:32:23.247108+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Virpax regains compliance with Nasdaq periodic filing rule; bid price deficiency remains

## Summary
- Received Nasdaq notice confirming compliance with periodic filing requirement under Listing Rule 5250(c)(1) as of Dec 7, 2023.
- Still subject to prior bid price deficiency (Rule 5550(a)(2)) from April 2023; compliance deadline is April 8, 2024.
- No other changes to listing status or business operations disclosed.

## SEC filing metadata
- accession: 0001213900-23-095247
- form_type: 8-K
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2023-12-13T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000121390023095247/0001213900-23-095247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000121390023095247/ea189951-8k_virpaxpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-095247
- JSON: https://secwatch.observer/filing/0001213900-23-095247.json
- Plain text: https://secwatch.observer/filing/0001213900-23-095247.txt

## Key facts
- Listing & Compliance Notices
  Virpax Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: noncompliance notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: April 10, 2023 with respect to the Company’s failure to maintain a minimum closing bid price of $1.00 per share on any business day over a thirty consecutive business day period, as required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) which the Company has until April 8, 2024 to comply with.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000121390023095247/0001213900-23-095247-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.